Clinical Trial

A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis

Study acronym: PEACOCX
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU). It is anticipated that up to 18 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time.
Trial Details
NCT Number NCT07427628
Lead Sponsor Quan Dong Nguyen
Conditions Non Infectious Uveitis
Enrollment 18 participants
Start Date 2026-03
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-23